NLRP3 inflammasome inhibitors (Ventyx Biosciences)

Ambroxol, a repurposed cough suppressant, shows potential as a disease-modifying therapy for Parkinson's by enhancing lysosomal function and clearing α-synuclein aggregates, with the GREAT trial currently evaluating its efficacy.

Ventyx Biosciences initiated a Phase 2 trial of VTX3232 for obesity and cardiometabolic risk factors, with topline data expected in the second half of 2025.

The NLRP3 protein inhibitors pipeline is robust, with over 20 companies developing more than 25 inhibitors targeting various inflammatory conditions.

Ventyx Biosciences advances VTX3232 into Phase 2 trials for early Parkinson's and obesity, expecting topline results in H1 and H2 2025, respectively.

Ventyx Biosciences has commenced a Phase 2a clinical trial of VTX3232 in patients with early Parkinson's disease, marking a significant step in neuroinflammatory disease treatment.